Alessandro Bartoloni to Compassionate Use Trials
This is a "connection" page, showing publications Alessandro Bartoloni has written about Compassionate Use Trials.
Connection Strength
0.150
-
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
Score: 0.150
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.